Caplacizumab (VWF A1-domein) - Onderzoeksraster Biosimilar
Gecertificeerd

Caplacizumab (VWF A1-domein) - Onderzoeksraster Biosimilar

Catalog #: 10-476
Maat: 0.1 mg

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100
Technische Documentatie

Technische Specificaties

Background

Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,6 and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.

Immunogen

Humanized / VWF A1 domain [Homo sapiens]

Clonality

• Recombinant Monoclonal

Conjugation

Unconjugated

Type

Primary Antibodies, Biosimilars

Source

CHO cells

Field of Research

Neuroscience

Purification

>95%

Concentration

Batch dependent

Buffer

PBS buffer pH7.5

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

Fragment

VH-VH

NCBI Organism

Homo sapiens

Other Product Names

ALX-0081, PMP12A2h1-linker AAA-PMP12A2h1, caplacizumab-yhdp

Beschrijving

Caplacizumab (VWF A1-domein) - Onderzoeksraster Biosimilar Beschikbaar in 0.1 mg. Bestel eenvoudig online met snelle levering.

Specificaties

ProductnaamCaplacizumab (VWF A1-domein) - Onderzoeksraster Biosimilar
Categorie
Beschikbare grootte0.1 mg
Catalogusnummer10-476